Experimental drug tested for Tough-to-Treat breast cancer
NCT ID NCT06162351
Summary
This study tested an experimental drug called PLX038 for people with advanced triple-negative breast cancer that had stopped responding to other treatments. Participants received the drug through an IV every three weeks to see if it could shrink their tumors. The trial was terminated early and enrolled only 14 people, so results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Curie
Paris, 75248 Cedex, France
-
Institut Curie
Saint-Cloud, 92210, France
Conditions
Explore the condition pages connected to this study.